NCT01001403

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Conditions

• Liver Transplantation
• Postreperfusion Syndrome

Interventions

Type	Name	Description
DRUG	Nafamostat	0.2 mg/kg as bolus 1 minute before reperfusion
DRUG	Normal saline	10 ml of normal saline

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-03-01
• Completion: 2010-04-01
• First posted: 2009-10-26
• Last updated: 2010-05-11
• Results posted: 2010-05-03

Locations

1 site across 1 country: South Korea